There are few RCT\u2019s
comparing different BCG strains. As a consequence, there is limited
information available on the difference in their efficacy in the treatment
of patients with NMIBC. A trial from 1995 showed that an induction
course BCG RIVM significantly reduced the number of recurrences
compared to an induction course of BCG Tice [Vegt et al, J Urol 1995].
A recently published trial [Rentsch et al, Eur Urol 2014] also found an
induction course of BCG Connaught to be significantly better in the
reduction of recurrences than an induction course of BCG Tice. We
retrospectively compared the outcomes after BCG Connaught and BCG
Tice in a large study cohort of high risk NMIBC patients, and looked at
recurrence, progression and cancer specific survival (CSS)
